RUBIN STEPHEN
No ORCID on file
· 98 papers in corpus
· active 2004-2011
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2011
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008